Physician profile
Bridgit V Nolan
NPI 1801117338
$3,537.03
in general payments reported to CMS, 2019-2025
24 companies · $478 in 2025
The $478 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.33 · 2020: $253 · 2021: $665 · 2022: $773 · 2023: $579 · 2024: $749 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782 · Education: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.87 |
| Education | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,038.81 | 2019-2025 | |
| Genzyme Corporation | $517.45 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $237.78 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $183.54 | 2021-2025 | |
| Lilly USA, LLC | $174.36 | 2020-2024 | Taltz, Ebglyss |
| Incyte Corporation | $155.60 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $145.88 | 2022-2024 | Sotyktu |
| Amgen INC. | $140.89 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $130.89 | 2020-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $109.21 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Allergan, INC. | $94.20 | 2021-2022 | |
| Almirall LLC | $87.02 | 2021-2025 | Klisyri |
| Biofrontera INC. | $79.99 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $68.34 | 2020-2021 | |
| Pfizer INC. | $57.56 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $54.57 | 2020-2023 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.44 | 2023-2025 | Arazlo, Jublia, Cabtreo |
| Janssen Biotech, INC. | $44.06 | 2022-2023 | Tremfya |
| Organogenesis INC. | $38.55 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $38.41 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $30.76 | 2024-2025 | Nemluvio |
| Taro Pharmaceuticals USA, INC. | $24.39 | 2019 | |
| Dermavant Sciences, INC. | $23.00 | 2023 | Vtama |
| Merz North America, INC. | $17.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgit Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.